Premarin* (Estrogens, Conjugated) — Medicare Part D spending
Wyeth/Pfizer* · Rank #172 by total Part D spend · CMS data year 2023
Medicare Part D spent $279,329,987 on Premarin* (Estrogens, Conjugated) in 2023, the #172 drug by total Part D spending out of 3,598 drugs. That worked out to about $11.34 per dosage unit, $437 per claim and $1,157 per beneficiary, across 639,745 claims for 241,518 beneficiaries. Average spending per dosage unit rose +6.6% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Premarin* (Estrogens, Conjugated) spending at a glance (2023)
| Metric | Premarin* (Estrogens, Conjugated) |
|---|---|
| Total Part D spending (2023) | $279,329,987 |
| Total spending (2022) | $281,548,605 |
| Year-over-year change in total spending | -0.8% |
| Average spending per dosage unit (2023) | $11.34 |
| Change in spend per dosage unit (YoY) | +6.6% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +5.7% |
| Average spending per claim (2023) | $437 |
| Average spending per beneficiary (2023) | $1,157 |
| Total claims (2023) | 639,745 |
| Beneficiaries (2023) | 241,518 |
| Total dosage units (2023) | 27,362,743 |
| Manufacturer(s) | Wyeth/Pfizer* |
| National rank by total spend (of 3,598 drugs) | #172 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $281,548,605 | $279,329,987 | -0.8% |
| Avg spend per dosage unit | $10.63 | $11.34 | +6.6% |
| Avg spend per claim | $412 | $437 | — |
| Avg spend per beneficiary | $1,116 | $1,157 | — |
| Total claims | 683,408 | 639,745 | — |
| Beneficiaries | 252,243 | 241,518 | — |
How Premarin* compares with nearby drugs
Drugs with total Part D spending closest to Premarin* (Estrogens, Conjugated):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Premarin* (Estrogens, Conjugated) (this drug, #172) | $279,329,987 | $11.34 | +6.6% |
| Bydureon Bcise (Exenatide Microspheres) (#170) | $284,056,759 | $244.15 | +3.1% |
| Xeljanz (Tofacitinib Citrate) (#171) | $279,993,121 | $94.17 | +6.8% |
| Synjardy XR (Empagliflozin/Metformin HCl) (#173) | $278,415,269 | $14.67 | +4.6% |
| Orgovyx (Relugolix) (#174) | $276,597,252 | $89.52 | +6.0% |
| Cimzia (Certolizumab PEGol) (#175) | $275,055,734 | $5,649.06 | +6.7% |
Frequently asked questions
How much does Medicare Part D spend on Premarin*?
Medicare Part D spent $279,329,987 on Premarin* (Estrogens, Conjugated) in 2023 (the latest CMS data year), across 639,745 claims for 241,518 beneficiaries. That ranks #172 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Premarin*?
In 2023, the weighted average Medicare Part D spending per dosage unit for Premarin* (Estrogens, Conjugated) was $11.34. Compared with 2022 it rose +6.6%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Premarin*?
CMS attributes Premarin* (Estrogens, Conjugated) to Wyeth/Pfizer* in the 2023 Part D spending file. Average spending per claim was $437 and per beneficiary $1,157.
Is the Premarin* figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20